Medical Advocates
Lamivudine (Epivir)
 
HBV Journal Citations

General Reports
 Pharmacokinetics
Viral Dynamics
 Resistance
 Adverse Events
 Efficacy
 Case Studies
 Prevention
Diagnostics/Monitoring
 Transplantation

 
Lamivudine Main Page Main New/Newsworthy  Home Page      

Last Update:  February 06, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader .

General/Miscellaneous Reports
          
 
Detection of Hepatitis B Virus Variants in HBV Monoinfected and HBV/HIV
Coinfected Iranian Patients under Lamivudine Treatment.
 Aghasadeghi MR, Bahramali G, Sadat SM, et al
Curr HIV Res. 2011 Jun 14.
 Abstract

Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle
regulatory proteins.
Chin R, Earnest-Silveira L, Koeberlein B, Franz S,et al  
Antivir Ther. 2008;13(2):221-30
 Abstract
 
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated
with lamivudine.
Kobayashi M, Suzuki F, Akuta N,  et al   
J Med Virol. 2007 Oct;79(10):1472-7.
 Abstract
 
Association between lamivudine sensitivity and the number of substitutions in the reverse
transcriptase region of the hepatitis B virus polymerase.
 Fukai K, Zhang KY, Imazeki F, et al
J Viral Hepat. 2007 Sep;14(9):661-6.
Abstract
 
FULL TEXT ARTICLE
 Effects of lamivudine on the function of dendritic cells derived from patients with chronic
hepatitis B virus infection.
Zheng PY, Zhang DY, Lu GF, et al  
World J Gastroenterol. 2007 Sep 14;13(34):4641-5
 Paper
 
Changes in viral loads of lamivudine-resistant mutants during entecavir therapy.
 Suzuki F, Suzuki Y, Akuta N, et al
 Hepatol Res. 2007 Jun 15;
 Abstract 
 
Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients
on long-term lamivudine therapy.
Kazim SN, Chauhan R, Das BC, Sarin SK, et al
J Gastroenterol Hepatol. 2006 Oct;21(10):1525-32.
 Abstract
 
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
Hache C, Villeneuve JP.
Expert Opin Pharmacother. 2006 Sep;7(13):1835-43.
Abstract
 
Effect of lamivudine treatment on the quality of life of chronic hepatitis B
Yi LX, Yang X, Wang XW. 
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Jun;31(3):396-9.
 Abstract
 
Comparison of sequence changes of precore and core promoter regions in HBeAg-positive
chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH, Lee CM, Lu SN, Changchien CS, et al
 J Hepatol. 2006 Jan;44(1):76-82.
 Abstract
 
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained
response to therapy.
Sung JJ, Wong ML, Bowden S, et al
Gastroenterology. 2005 Jun;128(7):1890-7.
 Abstract
 
FULL-TEXT ARTICLE
YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological
analysis with long-term lamivudine therapy after liver transplantation.
Pei F, Ning JY, You JF,et al
 World J Gastroenterol. 2005 May 14;11(18):2714-9.
 Paper
 
Relationship between B virus hepatitis genotypes and therapeutic efficacy in early
treatment for chronic hepatitis B by using lamivudine.
Song SJ, Zhuang H, Yan J, Wei HS   
Zhonghua Yu Fang Yi Xue Za Zhi. 2005 May;39(3):203-5.
 Abstract
 
Factors associated with response to lamivudine: Retrospective study in a tertiary care
clinic serving patients with chronic hepatitis B.
Hann HW, Jonsson Funk ML, et al
 J Gastroenterol Hepatol. 2005 Mar;20(3):433-40.
 Abstract
 
Body surface area is an independent factor contributing to the effects of lamivudine
treatment.
Nakamuta M, Kotoh K, Tanabe Y,  
Hepatol Res. 2005 Jan;31(1):13-17
 Abstract

Lamivudine therapy for chronic hepatitis B in renal transplant recipients.
Durlik M, Lewandowska D. 
Eur J Gastroenterol Hepatol. 2004 Dec;16(12):1261-1264.
 Abstract
 
Prophylactic Lamivudine Administration Prevents Exacerbation of Liver Damage in
HBe Antigen Positive Patients with Hepatocellular Carcinoma Undergoing
Transhepatic Arterial Infusion Chemotherapy.
Nagamatsu H, Itano S, Nagaoka S, et al  
Am J Gastroenterol. 2004 Dec;99(12):2369-75
 Abstract
 
Comparison of clinical outcome between patients continuing and discontinuing
lamivudine therapy after bochemical breakthrough of YMDD mutants.
Chen CH, Lee CM, Lu SN,  et al 
EvJ Hepatol. 2004 Sep;41(3):454-61
 Abstract

Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for
chronic hepatitis B virus infection.
Tanaka Y, Yeo AE, Orito E, et al 
J Gastroenterol. 2004 Aug;39(8):769-75.
 Abstract
Pharmacokinetics
          
 
Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine
Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams
Once Daily and 150 Milligrams Twice Daily.
Yuen GJ, Lou Y, Bumgarner NF et al. 
Antimicrob Agents Chemother. 2004 Jan;48(1):176-82.
 Abstract

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily
administration in patients with HIV.
Bruno R, Regazzi MB, Ciappina V, et al.
Clin Pharmacokinet 2001;40(9):695-700
Abstract
Viral Dynamics
 
 
Viral genotype and baseline load predict the response to adefovir treatment in
lamivudine-resistant chronic hepatitis B patients.
Buti M, Elefsiniotis I, Jardi R, et al
J Hepatol. 2007 May 24;
Abstract

Intrahepatic CD8(+) T-lymphocyte response is important for therapy-induced viral
clearance in chronic hepatitis B infection.
Tang TJ, Kwekkeboom J, Mancham S, et al
J Hepatol. 2005 Jul;43(1):45-52.
Abstract
Resistance
 
 
High incidence of lamivudine-resistance associated vaccine-escape HBV mutant among HIV-coinfected patients on prolonged antiretroviral therapy.
 Pal A, Sarkar N, Saha D,  et al
Antivir Ther. 2015 Feb 5
 Abstract

Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV
and hepatitis B.
 Taramasso L, Caligiuri P, Di Biagio A, et al
J Med Virol. 2011 Nov;83(11):1905-8.
Abstract

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without
evidence of lamivudine resistance.
 Kurashige N, Ohkawa K, Hiramatsu N, et al
J Gastroenterol. 2009 May 28.
Abstract

FULL TEXT ARTICLE
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with
lamivudine-resistant chronic hepatitis B.
Nam SW, Bae SH, Lee SW, et al
 World J Gastroenterol. 2008 Mar 21;14(11):1781-1784.
 Paper
 
FULL TEXT ARTICLE
 The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated
chronic hepatitis B patients: an opportunity for therapy reevaluation.
França PH, Coelho HS, Brandão CE, et al
Braz J Med Biol Res. 2007 Dec;40(12):1605-14.
 Paper
 
Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine
treatment failure.
Svedhem V, Bergroth T, Lidman K, Sönnerborg A.
HIV Med. 2007 Nov;8(8):504-10.
 Abstract
 
Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B
virus infection.
Ramezani A, Velayati AA, Roshan MR,et al  
Int J Infect Dis. 2007 Oct 20;
 Abstract
 
Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV
DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP, Li LJ, Du WB, Li MW, et al 
J Viral Hepat. 2007 Nov;14(11):767-74.
 Abstract
 
Prolonged Persistence of Lamivudine-resistant Mutant and Emergence of New Lamivudine-
resistant Mutants Two Years After Lamivudine Withdrawal in HBsAg-positive Chronic
Hepatitis Patient: A Case Report.
Orlando R, Tosone G, Portella G, et al  
Infection. 2007 Oct 25;
 Abstract
 
Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological
factors.
Thompson AJ, Ayres A, Yuen L, et al
J Gastroenterol Hepatol. 2007 Jul;22(7):1078-1085.
Abstract
 
Predictors of Lamivudine resistance in patients with chronic hepatitis B virus infection.
Heo J, Cho M, Cho BM, et al
Korean J Hepatol. 2007 Jun;13(2):157-65
 Abstract
 
FULL-TEXT ARTICLE
 Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients
before and after lamivudine treatment.
Lee CZ, Lee HS, Huang GT, et al 
World J Gastroenterol. 2006 Sep 7;12(33):5301-5.
 Paper
 
A prospective study of the evolution of lamivudine resistance mutations in patients with
chronic hepatitis B treated with lamivudine.
Zoulim F, Poynard T, Degos F, et al 
J Viral Hepat. 2006 Apr;13(4):278-88.
 Abstract
 
Dynamics of hepatitis B virus resistance to Lamivudine.
Pallier C, Castera L, Soulier A, et al   
J Virol. 2006 Jan;80(2):643-53
 Abstract
 
Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.
 Alvarado-Esquivel C, de la Ascension Carrera-Gracia M, Conde-Gonzalez CJ, et al
J Antimicrob Chemother. 2005 Dec 22;
 Abstract
 
Virus and transaminase levels determine the emergence of drug resistance during long-term
lamivudine therapy in chronic hepatitis B.
Chang ML, Chien RN, Yeh CT, Liaw YF  
J Hepatol. 2005 Jul;43(1):72-7.
 Abstract
 
Overlapping Gene Mutations of Hepatitis B Virus in a Chronic Hepatitis B Patient with
Hepatitis B Surface Antigen Loss during Lamivudine Therapy.
Lee SY, Choi MS, Lee D, et al
J Korean Med Sci. 2005 Jun;20(3):433-7
 Abstract
 
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both
lamivudine and adefovir.
Brunelle MN, Jacquard AC, Pichoud C, et al
Hepatology. 2005 Jun;41(6):1391-8.
 Abstract
 
Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-
HBV co-infected individuals.
Cooley L, Ayres A, Bartholomeusz A, et al.
AIDS. 2003 Jul 25;17(11):1649-1657.
Abstract

Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A, Bartholomeusz A, Lau G, et al
J Clin Virol 2003 May;27(1):111-6
 Abstract
 
  Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Liaw YF.
J Gastroenterol Hepatol 2002 Dec;17 Suppl 3:S333-S337
 Abstract
 
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic
hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -
an open-cohort study.
 Akuta N, Tsubota A, Suzuki F, et al.
 J Hepatol 2003 Jan;38(1):91-7
 Abstract

Comparison of anti-hepatitis B virus activities of Lamivudine and clevudine by a quantitative
assay.
Abdelhamed AM, Kelley CM, Miller TG , et al.  
Antimicrob Agents Chemother 2003 Jan;47(1):324-36
 Abstract

Repeated jaundice due to YMDD mutant in a patient with prolonged lamivudine therapy for
chronic hepatitis B under prednisolone treatment for Still's disease.
Joh R, Hasegawa K, Torii N, et al.
Intern Med 2002 Sep;41(9):701-5
 Abstract

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients
co-infected  with the human  immunodeficiency virus in a Dutch cohort.
Wolters LM, Niesters HG, Hansen BE, et al.
J Clin Virol 2002 Apr;24(3):173-181
 Abstract

Prevalence and profile of mutations associated with lamivudine therapy in Indian patients
 with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM, Kazim SN, Khan LA, et al.
J Med Virol 2002 Nov;68(3):311-8
 Abstract

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B
virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K, Xiong X, Yang H, et al.
J Virol 2001 May;75(10):4771-4779
 Abstract

FULL-TEXT ARTICLE
 Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients
Coinfected with HBV and Human Immunodeficiency Virus.
 Thibault V, Benhamou Y, Seguret C, et al.
J Clin Microbiol 1999 Sep;37(9):3013-3016
Paper

 Sequential treatment with lamivudine and interferon monotherapies in patients with chronic
hepatitis B not responding to interferon alone: Results of a pilot study.
Serfaty L, Thabut D, Zoulim F, et al.
Hepatology 2001 Sep;34(3):573-577
 Abstract

FULL-TEXT ARTICLE
 A Dose Ranging Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of
Lamivudine  in Children and Adolescents with Chronic Hepatitis B. 
Sokal EM, Roberts EA, Mieli-Vergani G, et al.
 Antimicrob Agents Chemother 2000 Mar;44(3):590-597
Paper

  
Adverse Events
 
 
FULL TEXT ARTICLE
Effects of lamivudine on serum albumin levels correlate with pretreatment
HBV-DNA levels in cirrhotic patients.
Nakamuta M, Kotoh K, Enjoji M, et al
Comp Hepatol. 2007 May 1;6:3
 Paper
 
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a
YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
Law JK, Ali JA, Harrigan PR, et al  
Am J Hematol. 2006 Aug 25;
 Abstract
 
Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic
mitochondrial damage.
Fodale V, Mazzeo A, Pratico C, et al 
Anaesthesia. 2005 Aug;60(8):806-810.
 Abstract

Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant.
Kagawa T, Watanabe N, Kanouda H,et al.
World J Gastroenterol. 2004 Jun 1;10(11):1686-7.
 Abstract
 
HBV associated nephrotic syndrome: resolution with oral lamivudine.
Connor FL, Rosenberg AR, Kennedy SE, Bohane TD.
Arch Dis Child 2003 May;88(5):446-9
 Abstract

Lamivudine/Corticosteroid Therapy
 
  Severe Exacerbation of Chronic Hepatitis B During Therapy with Corticosteroids and
Lamivudine Therapy and Successful Short-term Combination Therapy with Interferon-
beta and Interferon-gamma
Musch E, Malek M, Chrissafidou A.
 Z Gastroenterol 2003 May;41(5):425-428
 Abstract
Case Studies
          
  Fatal fulminant hepatitis B after withdrawal of prophylactic Lamivudine in hematopoietic
stem cell transplantation patients.
Lin PC, Poh SB, Lee MY, Hsiao LT, et al
Int J Hematol. 2005 May;81(4):349-51.
 Abstract
 
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination
therapy for lamivudine failure.
Maynard M, Parvaz P, Durantel S, et al  
J Hepatol. 2005 Feb;42(2):279-81.
 Abstract

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to
rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y, Tanaka J, Kawamura T, et al 
Ann Hematol. 2003 Sep 26
 Abstract
Prevention
          
 
Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and
reactivation-related mortality in chemotherapy patients: a meta-analysis.
Martyak LA, Taqavi E, Saab S.
Liver Int. 2007 Nov 1;
Abstract
 
FULL TEXT ARTICLE
 Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with
lamivudine-resistant YMDD mutant.
Yang Y, Zhang Q, Cai CJ, et al  C
hin Med J (Engl). 2007 Aug 20;120(16):1400-3.
Abstract
 
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B
following liver transplantation.
Gane EJ, Angus PW, Strasser S, et al
Gastroenterology. 2007 Mar;132(3):931-7.
Abstract
 
Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic
hepatitis B virus infection.
Kohrt HE, Ouyang DL, Keeffe EB.
Aliment Pharmacol Ther. 2006 Oct 1;24(7):1003-16.
 Abstract
 
Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
Shitrit AB, Kramer MR, Bakal I, et al 
Ann Thorac Surg. 2006 May;81(5):1851-2.
 Abstract
 
Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with
hematologic malignancies treated with chemotherapy-A prospective case series.
Vassiliadis T, Garipidou V, Tziomalos K, et al
 Am J Hematol. 2005 Oct 24;80(3):197-203
Abstract

Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma
with lamivudine.
Yeo W, Hui EP, Chan AT, Ho WM, et al   
Am J Clin Oncol. 2005 Aug;28(4):379-84.
 Abstract

Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus
Jia J, Lin F. 
Zhonghua Gan Zang Bing Za Zhi. 2004 Oct 20;12(10):628-629.
 Abstract
 
Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from
anti-HBc-positive donors?
Loss GE Jr, Mason AL, Nair S, et al  
 Liver Transpl. 2003 Dec;9(12):1258-6
 Abstract
 
Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.
Lim LL, Wai CT, Lee YM, et al.  
Aliment Pharmacol Ther 2002 Nov;16(11):1939-44
 Abstract
 
Additional benefit of lamivudine treatment as a preventive therapy for hepatic encephalopathy
in patients with decompensated liver cirrhosis associated with
hepatitis B.
Hanada S, Kumashiro R, Kaji R, et al.
Int J Mol Med 2002 Nov;10(5):647-8
 Abstract
Diagnostics/Monitoring
 
 
Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.
 Gramenzi A, Loggi E, Micco L, et al
J Viral Hepat. 2011 Oct;18(10):e468-74
 Abstract

Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant
strains and comparison with direct sequencing and line probe assays.
Lupo J, Larrat S, Hilleret MN, Germi R, et al 
J Virol Methods. 2008 Nov 25
 Abstract
 
FULL TEXT ARTICLE
Determination of lamivudine-resistant variants of hepatitis B virus by denaturing gradient gel electrophoresis:
A novel approach to monitoring drug resistance.
Bielawski KP, Al-Soud WA, Stalke P,et al 
Med Sci Monit. 2008 May;14(5):CR281-285
 Paper
 
Hepatitis B Virus Core-related Antigens as a Marker for Monitoring of Chronic Hepatitis B
Infection.
Wong DK, Tanaka Y, Lai CL,  et al
J Clin Microbiol. 2007 Oct 17;
Abstract
 
Evolution of Primary and Compensatory Lamivudine-Resistance Mutations during
Long-term Lamivudine Treatment in Chronic HBV-Infected Patients Assessed by a
Line Probe Assay.
Libbrecht E, Doutreloigne J, Van De Velde H, et al  
J Clin Microbiol. 2007 Oct 3;
 Abstract

Rapid Detection of Lamivudine-Resistant Hepatitis B Virus Mutations by PCR-Based
Methods.
Chieochansin T, Chutinimitkul S, Payungporn S, et al
Tohoku J Exp Med. 2006 Sep;210(1):67-78.
Abstract
Transplantation
 
 
Adherence to Lamivudine After an Early Withdrawal of Hepatitis B Immune Globulin Plays an
Important Role in the Long-Term Prevention of Hepatitis B Virus Recurrence.
Buti M, Mas A, Prieto M, et al
Transplantation. 2007 Sep 15;84(5):650-654.
 Abstract
 
FULL TEXT ARTICLE
 Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with
lamivudine-resistant YMDD mutant.
Yang Y, Zhang Q, Cai CJ, et al  
Chin Med J (Engl). 2007 Aug 20;120(16):1400-3.
Paper
 
Prophylaxis of recurrent hepatitis B in chinese patients after liver transplantation using
Lamivudine combined with hepatitis B immune globulin according to the titer of antibody to
hepatitis B surface antigen.
Jiao ZY, Jiao Z.
Transplant Proc. 2007 Jun;39(5):1533-6.
Abstract
 
Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis
delta virus coinfection.
Caccamo L, Agnelli F, Reggiani P, et al
Transplantation. 2007 May 27;83(10):1341-4
 Abstract

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B
following liver transplantation.
Gane EJ, Angus PW, Strasser S, et al
Gastroenterology. 2007 Mar;132(3):931-7.
Abstract

Lamivudine Main Page Main New/Newsworthy  Home Page      

Lamivudine HBV Data
Journal Papers, Abstracts, and Commentaries